Correlation Between Fidelity MSCI and Franklin Genomic

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Fidelity MSCI and Franklin Genomic at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Fidelity MSCI and Franklin Genomic into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Fidelity MSCI Financials and Franklin Genomic Advancements, you can compare the effects of market volatilities on Fidelity MSCI and Franklin Genomic and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Fidelity MSCI with a short position of Franklin Genomic. Check out your portfolio center. Please also check ongoing floating volatility patterns of Fidelity MSCI and Franklin Genomic.

Diversification Opportunities for Fidelity MSCI and Franklin Genomic

-0.72
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Fidelity and Franklin is -0.72. Overlapping area represents the amount of risk that can be diversified away by holding Fidelity MSCI Financials and Franklin Genomic Advancements in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Franklin Genomic Adv and Fidelity MSCI is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Fidelity MSCI Financials are associated (or correlated) with Franklin Genomic. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Franklin Genomic Adv has no effect on the direction of Fidelity MSCI i.e., Fidelity MSCI and Franklin Genomic go up and down completely randomly.

Pair Corralation between Fidelity MSCI and Franklin Genomic

Given the investment horizon of 90 days Fidelity MSCI Financials is expected to generate 0.9 times more return on investment than Franklin Genomic. However, Fidelity MSCI Financials is 1.12 times less risky than Franklin Genomic. It trades about 0.09 of its potential returns per unit of risk. Franklin Genomic Advancements is currently generating about 0.01 per unit of risk. If you would invest  4,726  in Fidelity MSCI Financials on September 1, 2024 and sell it today you would earn a total of  2,605  from holding Fidelity MSCI Financials or generate 55.12% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Fidelity MSCI Financials  vs.  Franklin Genomic Advancements

 Performance 
       Timeline  
Fidelity MSCI Financials 

Risk-Adjusted Performance

15 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Fidelity MSCI Financials are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. Despite quite uncertain fundamental indicators, Fidelity MSCI disclosed solid returns over the last few months and may actually be approaching a breakup point.
Franklin Genomic Adv 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Franklin Genomic Advancements has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong essential indicators, Franklin Genomic is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors.

Fidelity MSCI and Franklin Genomic Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Fidelity MSCI and Franklin Genomic

The main advantage of trading using opposite Fidelity MSCI and Franklin Genomic positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Fidelity MSCI position performs unexpectedly, Franklin Genomic can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Franklin Genomic will offset losses from the drop in Franklin Genomic's long position.
The idea behind Fidelity MSCI Financials and Franklin Genomic Advancements pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Other Complementary Tools

Fundamental Analysis
View fundamental data based on most recent published financial statements
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency